• Yan Liu, Hai-Chao Yu, Jun Zhang, Chang Chen, Jin-Tang Cheng, Zong-Hua Song, and An Liu.
• Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China.
• Zhongguo Zhong Yao Za Zhi. 2018 Nov 1; 43 (21): 4356-4360.

Abstract"One drug was produced by many companies" is common in Chinese patent medicines. The quality and price of products from different manufacturers varies widely, and the efficacy is inconsistency. In order to ensure the quality of Chinese patent medicines and promote "Healthy national program" implementation, it is necessary to study the current status of Chinese patent medicines and carry out the evaluation criteria over quality as the core management of high grade Chinese patent medicines, which is set up to reflect the evaluation strategy and method of Chinese patent medicines from raw material, production, quality control, reevaluation and competitive power to the whole chain of brand construction. It aims to reveal the quality discrepancy from different manufacturers over the same Chinese patent medicines. The research and application will select a serials of high grade quality products, and provide reference basis for the scientific and reasonable price formation mechanism of Chinese patent medicines and purchasing drugs by centralized bidding, guide healthy competition in the market and promote the implementation of "healthy China 2030 program".Copyright© by the Chinese Pharmaceutical Association.

11 keywords...

hide…